Get Your 2017 ASIPP Meeting Mobile APP
To get the ASIPP® Annual Meeting 19 Mobile APP:
- Go to APP store
- Search ‘asipp annual meeting 19’
- Download
- Setup the APP
- APP Event Code: asipp19
To access APP from tablet or Computer go to:
https://crowd.cc/asipp19
Your Event Code (if necessary): asipp19
|
|
|
ASIPP Room Block Closed, But Rooms Still Available
ASIPP is proud to announce that
Mayor Rudolph "Rudy" Giuliani will be addressing the attendees of the 2017 ASIPP Annual Meeting to be held April 20- 22, 2017 in Las Vegas. Mayor Giuliani will be one of our keynote speakers on Saturday, April 22, 2017 at Caesar's Palace in Vegas.
Other prestigious guest speakers lined up for this year's meeting include:
- Congressman Ed Whitfield: ASIPP is Moving Forward, Long-time friend of ASIPP and recently retired Congressman for Kentucky
- Abraham Verghese, MD, MACP - Keynote Speaker: Delivering Humanistic Care in the Era of High Tech and Lean Resources Stanford University School of Medicine, Stanford, CA Abraham Verghese is a physician-author, Professor for the Theory and Practice of Medicine at Stanford University Medical School and Senior Associate Chair of the Department of Internal Medicine.
- Robert Wachter, MD: The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine's Computer Age University of California San Francisco School of Medicine, San Francisco, CA Dr. Robert Wachter is Professor and Associate Chair of the Department of Medicine at the University of California, San Francisco. He was named one of the 50 most influential physicians in the U.S. for each of the past 7 years.
- Robert Laszewski: US Health Care: Present Status and Future Directions for Independent Physician President, Health Policy and Strategy Associates, LLC. Robert Laszewski is a frequent speaker at ASIPP events. He is the president of Health Policy and Strategy Associates, Inc. (HPSA), a policy and marketplace consulting firm dealing with health policy and market change.
- Richard North, MD: Evolving Concepts of Neuromoducation: Past, Present and Future President, the Neuromodulation Foundation, Inc. Dr. Richard North has directed the Neurosurgery Spine Service for 16 years at the Johns Hopkins University School of Medicine. He has received The American Academy of Pain Medicine's Founder's Award, and the North American Neuromodulation Society's Lifetime Achievement Award in the field of implanted electrical stimulation devices.
- Philippe Hernigou, MD - Keynote Speaker: Innovations in Stem Cell Therapy for Musculoskeletal Injuries Chief of Surgery & Professor of Hospital Henri Mondor, University, Paris. Dr. Hernigou served as a Member of the Board of Scientific Advisors of Stemedica Cell Technologies, Inc. He has used autologous bone marrow concentrate (BMC) to treat orthopedic pathologies since 1990.
- Laxmaiah Manchikanti: Evolution or Innovation: Current Perspectives and Future Strategies, Chairman of the Board and CEO, ASIPP
In addition, ASIPP will be offering multiple afternoon breakout sessions includes sections on:
- Compliance Billing and Coding
- Responsible Controlled Substance Prescribing
- Endoscopic Decompression
- Regenerative Medicine
- Practce Management
- Ambulatory Surgery Center Payment Systems
- Emerging Concepts in IPM
- Abstract Session
- Current and Future Concepts in IPM
|
|
|
ASIPP is Offering Advocacy Clinics for the First Time Ever
Sign Up Now or at the Meeting!
During the afternoon on Friday, you are invited to take advantage of the expertise of ASIPP’s Counsel to prepare you to not only contact and share concerns with your local representatives, but also prepare you to join ASIPP when we visit our Senators and Congressmen in Washington, DC.
This is your time to learn the issues that affect Interventional Pain Management and more importantly, learn how to express your concerns to local, state and national lawmakers.
ASIPP has been extremely effective in being heard on the Hill. We have been able to have our concerns not only voiced but addressed by legislation. ASIPP has been able to turn the tide on some bills to help, instead of hurt, the future of IPM.
Join the winning team! Start at this year’s annual meeting. Senator and Randi Hutchinson, Congressman Ed Whitfield and Jeff MacKinnon, and Jeff Mortier and Sarah Walters will all be paired off in three rooms available to you at 30 minute intervals Friday afternoon from 1 pm to 5 pm
These slots are available on a first come, first serve basis and limited to six people per half-hour session. Perfect for you to sign up with doctors from your practice or even members from your state!
Sign up sheets will be available at the ASIPP booth at the annual meeting.
To sign up before the annual meeting, please email hlong@asipp.org with the time, names and team preference (if you have one). You will receive email verification for your spot – if it is still available.
|
|
|
Save The Date!
Board Certification Testing Available in June in Orlando, FL
Make plans now to take one of the following exams during the June 16 – 18th course in Orlando, FL.
We will be offering the following exams (more details will be available next week)
and
Written and Oral Exams will be held on Saturday, June 17. Hand-on lab exam will be Sunday 18th
|
|
|
Trump Says Health-Care Revamp Still Priority Ahead of Tax Overhaul
|
|
President Donald Trump said he would keep pressing to enact a health-care overhaul even if it means delaying another one of his policy goals: revamping the tax code.
Last month, House Republicans conceded they didn’t have enough votes to pass their health-care bill, despite an aggressive lobbying effort by the White House. Mr. Trump and congressional Republicans say they haven’t given up and are still working to assemble the votes needed to overturn major pieces of former President Barack Obama’s Affordable Care Act.
In an interview with Fox Business Network that will air Wednesday morning, Mr. Trump said that his overriding legislative priority is passing the health-care law, though he said he won’t wait indefinitely to turn his attention to the tax overhaul.
Wall Street Journal
Access to this article may be limited.
|
|
|
Finally, an Online Journal for Interventional Pain Management Case Reports, as well as Brief Reports and Reviews
|
Inaugural Issue Online Now!
Inside this inuaugural issue of Interventional Pain Management Reports (IPM Reports) , we are featuring an impressive amount of case reports on Epidural Hematoma. These and much more informative manuscripts are found in the March 2017 issue of IPM Reports.
This issue includes:
- Five Epidural Hematoma-Related Articles
- Subcutaneous Botulinum Toxin Injections for Post-Craniotomy Scars
- Perioperative Ketamine Infusion for Reversing Opioid-Induced Hyperalgesia
- Platelet Rich Plasma in the Treatment Algorithm of Knee Osteoarthritis
|
|
|
Cigna reports 12 percent cut in opioid use among U.S. customers
As the epidemic of opioid abuse continues to take its toll on the U.S. healthcare system, health insurer Cigna Corp on Thursday reported a nearly 12 percent drop prescription opioid use among its customers in the past twelve months.
The abuse of opioids — a class of drugs that include heroin and prescription painkillers — has long been a concern. U.S. regulators and lawmakers have taken a number of steps to control the supply and use of opioids, but the healthcare system is struggling to cope with the rising number of addicts.
Reuters
|
|
|
FDA News
Arymo ER Launched for Chronic Pain
Egalet announced the launch of Arymo ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Arymo ER was initially approved by the Food and Drug Administration (FDA) in January 2017. It utilizes the proprietary Guardian Technology, which provides a physical and chemical barrier approach to deter abuse without the use of an opioid antagonist. This technology results in tablets that are difficult to manipulate when it comes to misuse and abuse.
MPR
New FDA Drug Meeting RoxyBond
RoxyBond (oxycodone hydrochloride immediate-release tablets), created by Inspirion Delivery Sciences, was evaluated by the FDA Advisory Board on Anesthetics, Analgesics and Addiction Medicine in Silver Springs, Maryland on April 5th, 2017 to be the first abuse deterrent immediate-release formulation. RoxyBond has physical and chemical barriers to deter intranasal and IV abuse.
The formulation utilizes Sentry Bond TM technology. To date, 9 drug formulations have been approved with abuse-deterrence of ER/LA opioids with no abuse-deterrent IR opioid formulations prior to RoxyBond. The vote for RoxyBond to be labeled as an abuse-deterrent product for nasal route was 19-1 yes and for IV route of abuse 16-4 yes. Finally, the vote for Roxybond to be approved for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate was 19-1 yes. These results from the FDA Advisory Board will be reviewed by the FDA for a final determination of the drug application in the near future.
|
|
|
The new White House drug czar has quite an idea for where to put nonviolent drug users
Marino appears to be in that camp as well, but his views are unlikely to influence the administration's policy in the same ways Sessions's views do. That's because the drug czar's office has traditionally played a limited role in setting policy --instead, it coordinates drug control strategy and funding across the federal government.
Still, with the selection of Marino, another piece of Trump's drug control strategy falls into place. In Congress, Marino voted multiple times against a bipartisan measure to prevent the Justice Department from going after state-legal medical marijuana businesses. (The measure ultimately passed.)
Similarly, he voted against a measure to allow Veterans Affairs doctors to recommend medical marijuana to their patients, as well as against a separate measure to loosen federal restrictions on hemp, a non-psychoactive variant of the cannabis plant with potential industrial applications.
Washington Post
|
|
|
Is Opioid-Induced Hyperalgesia Lessened by Switching to Buprenorphine?
In a prospective pilot study reported in the
Journal of Nature and Science, researchers at the University of Michigan observed changes in several measures of pain in patients suspected of opioid-induced hyperalgesia (OIH) after transitioning from opioids to buprenorphine.1
In the 2016 Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain, the risk for OIH was noted as an area of concern in addition to the potential for opioid abuse and overdose.2 Previous findings by the investigators of the current study show that “patients on opioids with persistently high pain scores reported a phenotype consistent with having a more centralized pain state (fibromyalgia-like presentation), which suggests the potential presence” of OIH.3 Patients with suspected OIH and taking >100 mg oral morphine equivalents (OME) were found to have lower pressure pain tolerance than those taking <100 mg OME.4 Although results of other recent studies indicate that
buprenorphine may represent a viable alternative for patients with pain who are exhibiting opioid dependence, these studies did not use quantitative sensory testing or examine phenotypic changes.5,6
The present study investigated pressure pain sensitivity and pain phenotyping in 20 patients transitioning from full µ-opioid agonists to buprenorphine for the treatment of suspected OIH.
|
|
|
New law quietly passed in Tennessee seen as big win for physician reimbursement: 5 things to know
Republican Tennessee Gov. Bill Haslam signed a bill requiring health insurers to notify physicians about mid-contract changes to reimbursements and fee schedules in advance.
Here are five things to know about the bill.
1. Gov. Haslam signed the legislation into law April 5. House Bill 498/Senate Bill 437, dubbed the "Provider Stability Act," will take effect Jan. 1, 2019.
2. The bill requires insurers to give providers at least a 60-day notice before changes are made to reimbursement rates in the sole discretion of the payer.
3. In addition, the measure prohibits payers from changing a provider's fee schedule more than once within a 12-month period. The bill also extends when insurers must notify providers about any fee schedule changes from 30 days to at least 90 days before the effective date.
4. While insurers argue the ability to change reimbursements and fee schedules can benefit policyholders, providers said the law will add financial predictability in payer-provider contracts, Times Free Press reports.
5. The Tennessee Medical Association, representing more than 9,000 physicians, has advocated for the bill — which it calls the "first of its kind" in the U.S. — since 2014. TMA President Keith Anderson, MD, said the measure "is a huge win for physicians and all healthcare providers in Tennessee" and it brings "some stability and predictability to the marketplace."
Becker’s Hospital Review
|
|
|
AL to become first state to classify Xanax as Schedule II drug
MONTGOMERY CO., AL (WSFA) - Alabama is on track to becoming the first state in the country to classify Xanax on the same level as opioids like oxycodone and fentanyl.
The Alabama Department of Public Health recently moved to reclassify Xanax as a Schedule II drug instead of a Schedule IV, at the suggestion of the Board of Medical Examiners. But, the pharmacy community say they've been left out of the conversation.
Dr. David Herrick, President of the Alabama Medical Association says the reclassification of Alprazolam, commercially known as Xanax, is going to save lives.
WSFA
|
|
|
Study: Physicians now spend half their time on computer tasks
Time spent by physicians is a key resource in health care delivery. This study used data captured by the access time stamp functionality of an electronic health record (EHR) to examine physician work effort. This is a potentially powerful, yet unobtrusive, way to study physicians’ use of time. We used data on physicians’ time allocation patterns captured by over thirty-one million EHR transactions in the period 2011–14 recorded by 471 primary care physicians, who collectively worked on 765,129 patients’ EHRs. Our results suggest that the physicians logged an average of 3.08 hours on office visits and 3.17 hours on desktop medicine each day. Desktop medicine consists of activities such as communicating with patients through a secure patient portal, responding to patients’ online requests for prescription refills or medical advice, ordering tests, sending staff messages, and reviewing test results. Over time, log records from physicians showed a decline in the time allocated to face-to-face visits, accompanied by an increase in time allocated to desktop medicine. Staffing and scheduling in the physician’s office, as well as provider payment models for primary care practice, should account for these desktop medicine efforts.
Health Affairs
|
|
|
Opioid/Benzodiazepine Combination Increases Risk of Overdose
Concurrent benzodiazepine and opioid use increased by 80% between 2001 and 2013 in the United States and significantly contributes to the overall population risk of opioid overdose, according to data published in the
BMJ.1
Eric E. Sun, MD, PhD, from the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and colleagues sought to identify trends in the concurrent use of opioids and benzodiazepine and identify the impact of these trends on hospital admissions and emergency room visits for opioid overdose.
The researchers identified 315,428 privately insured participants between 18 and 64 years of age who filled at least 1 prescription for an opioid. They calculated the annual percentage of opioid users with concurrent benzodiazepine use and the annual incidence of visits to the emergency room and inpatient admissions for opioid overdose.
|
|
|
Weight-Loss Drug May Help Curb Opiate Addiction
A recent study published in
ACS Chemical Neuroscience reported that a prescription weight-loss drug reduced the urge to use opiates like oxycodone.1
Current treatments to reduce opiate misuse operate by occupying opioid receptors in the brain to lessen the "signature euphoria." But due to cue reactivity, many who have tried available treatments often relapse when they are around the places, people, or objects they associate with opiate use. Researchers from the University of Texas Medical Branch (UTMB) at Galveston found that
lorcaserin, a serotonin 2C receptor agonist, decreased the craving for oxycodone in pre-clinical studies. Serotonin affects the part of the brain involved in drug reward and cue reactivity, particularly through the serotonin 2C receptors.
Earlier research by Kathryn Cunningham, PhD, professor at UTMB, had shown how lorcaserin reduced the number of times rats completed a simple task to earn a dose of cocaine. But much less was known about the role of serotonin 2C receptors in altering how opiates feel for the user.
|
|
|
OHSIPP Meeting
August 25-27, 2017
The Ohio Society of Interventional Pain Physicians (OHSIPP) has set the dates for its 2017 meeting.
Dates are Friday Aug 25 thru Sunday Aug 27, 2017.
The meeting will be held in Cincinnati at the Westin Hotel, 21 E 5th St , at Fountain Square .
Contact Michelle Byers for more information MichelleHByers@gmail.com
FSIPP Meeting
August 27 - 30, 2017
The Florida Society of Interventional Pain Physicians (FSIPP) has set the dates for its 2017 meeting
Dates are April 27-30, 2107
The meeting will be held in Orlando, FL at the Orlando World Center Marriott
Click Here for more information and to make reservation
|
|
|
|
|
|
|
